AlphAIAlphAI — Financial news for AI agents
fool.comSEP 172 min read$BLLN

BillionToOne CEO Liquidates Entire Directly-Held Stake in the Company for $3 Million

BillionToOne (BLLN) CEO Oguzhan Atay sold 30,331 shares for $3M on Sept 14, 2026, per SEC filing. The sale included cash-less option exercises and shares from his spouse's account, executed under a pre-planned trading plan. Atay retains 501,962 vested options and his spouse holds 157,168 shares. BLLN reported $109.4M Q2 2026 revenue, up 64% YoY, and forecasts $450M-$465M for full-year 2026.

Original reporting
fool.com
Published Sep 17, 2026, 6:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 6:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BillionToOne CEO Liquidates Entire Directly-Held Stake in the Company for $3 Million — source image
Source · fool.com
Decision brief

The 30-second read

$BLLNBearishLow
01

Why it matters

The disclosure provides fresh insider‑transaction data, offering a modestly actionable signal for short‑term traders.

02

Market read

First‑report insider sale of a CEO at a mid‑cap biotech, modest monetary size but notable due to complete stake disposal.

03

What to watch

Retention of ~500k vested options keeps the CEO aligned with long‑term upside, which could mitigate negative sentiment.

Relevance 5/10Novelty 6/10Timing: post‑market Sep 14, 2026

Background

Form 4 filing disclosed the CEO's complete direct‑hold disposal and spouse's minor sale, both executed via pre‑arranged trading plans.

Company-level read

Ticker impact

$BLLNBearishMedium confidence
Context

CEO Oguzhan Atay sold 30,331 Class A shares (~$3M) via a 10b5-1 plan, disposing his entire directly‑held stake.

Expected impact

Potential slight dip or flat price action as the market digests the disposal.

Evidence & confidence

Insider sales are often viewed as a negative signal, but the pre‑arranged plan reduces discretionary concern.

Market effects

Sector

Highlights potential valuation pressure on precision diagnostics peers as insider confidence is questioned.

Regional

Limited to U.S. biotech/diagnostics sector; no broader regional effect.

Global

Minimal global impact; primarily relevant to investors in BillionToOne and similar US‑listed biotech stocks.

Counterpoint

What could challenge this read

The sale was pre‑planned under a 10b5‑1 plan, suggesting no loss of confidence; the market may overreact.

Key entities

  • Executive
    Oguzhan Atay

    Chairman and CEO of BillionToOne, Inc.

  • Company
    BillionToOne, Inc.

    Precision molecular diagnostics firm (ticker BLLN).

Read at source← All news

Related articles

OCT 7
$BLLNLow

BillionToOne's Northstar Response Shows High Concordance In Advanced Cancer Study

BillionToOne (BLLN) published a study showing its Northstar Response liquid biopsy assay had high concordance with a commercial ctDNA assay in advanced cancer patients. The study of 61 patients found 94% agreement in tumor burden change direction, with Northstar Response aligning with clinical ground truth in discordant cases. The assay detects disease progression even when tumors evolve post-biopsy. BLLN shares closed at $22.71, down 0.79%.

rttnews.com2 min
OCT 7
$BLLNMedAI 8/10

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

BillionToOne (BLLN) announced a peer-reviewed study showing its Northstar Response® liquid biopsy assay performed on par or better than a tumor-informed assay in tracking cancer treatment. The study, published in The Journal of Liquid Biopsy, evaluated 169 samples from 61 patients, finding close alignment in results (R² = 0.97) and agreement in 94% of cases. Northstar Response detected disease progression in cases where the tumor-informed assay did not, highlighting its tumor-agnostic benefits.

globenewswire.com2 min
AUG 6
$BLLNMedAI 8/10

BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move - BillionToOne (NASDAQ:BLLN)

BillionToOne (NASDAQ:BLLN) shares fell 28.12% in after-hours after reporting Q2 results. For the quarter ended June 30, 2026, revenue rose to $109.4M from $66.6M, net income was $8.1M ($0.15/share), and gross margin improved to 70%. The company kept 2026 revenue guidance of $450M to $465M and plans Unity Fetal Risk Screen (Aug. 17) and Northstar Origin (Sept. 1) launches.

benzinga.com3 min
AUG 5
$BLLNMed

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

BillionToOne, Inc. (BLLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance MENLO PARK, CA, August 5, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to al

SEC EDGAR 8-K7 min
MAY 27
$BLLNMedAI 8/10

Billiontoone (BLLN) – Research Analysts’ Recent Ratings Updates

BillionToOne (NASDAQ: BLLN) saw multiple analyst rating and target changes. Weiss Ratings upgraded BLLN to “sell (d+)” (from “sell (d)”) on 5/15 and reaffirmed “sell (d)” on 5/1. Guggenheim raised its target to $120 (from $100) and kept a “buy” on 5/13. JPMorgan lifted its target to $125 and maintained “overweight” on 5/7. BTIG cut its target to $130 (from $140) while keeping “buy” on 5/7.

dailypolitical.com1 min